Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.43 |
| ▸ | IKBKB | O14920 | 6/20 | 0.41 |
| ▸ | CHUK | O15111 | 6/20 | 0.41 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177585 | 0.89 | CA1 (0.48) | NTRK1NTRK3NTRK2PDE5ACA1 | |
| SCHEMBL2180707 | 0.82 | TTK (0.52) | NTRK1NTRK3NTRK2PI4KB | |
| SCHEMBL12409495 | 0.82 | PI4KB (0.44) | NTRK1NTRK3NTRK2PI4KBPDE5A | |
| SCHEMBL12409487 | 0.82 | PTGS2 (0.45) | PI4KB | |
| SCHEMBL12409486 | 0.80 | CA1 (0.39) | NTRK1NTRK3NTRK2PDE5ACA1 | |
| SCHEMBL12409483 | 0.79 | PI4KB (0.44) | NTRK1NTRK3NTRK2PI4KBPDE5A | |
| SCHEMBL12409490 | 0.78 | FYN (0.42) | IKBKBCHUK | |
| SCHEMBL12409327 | 0.78 | FYN (0.47) | CA1CA2 | |
| SCHEMBL12409485 | 0.76 | CA1 (0.41) | NTRK1NTRK3NTRK2PI4KBPDE5A | |
| SCHEMBL12409445 | 0.75 | PI4KB (0.60) | PI4KBPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | NTRK1 3339/4885NTRK3 2491/4885NTRK2 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.